Progression-free survival is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". From Wikipedia
Presented at ASCO, the phase II study indicates that adding cetuximab to avelumab may offer a new treatment path for patients who progress after initial PD-1 therapy.
